A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Umeclidinium (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 30 Mar 2016 Results assessing pharmacokinetics (n=128) published in the European Journal of Drug Metabolism and Pharmacokinetics
- 09 Nov 2012 Planned End Date changed from 1 Mar 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.